Treatment-response analytics and digital cognitive endpoints for modern therapeutics development
Traditional clinical trials rely on infrequent, subjective assessments that miss subtle but meaningful treatment effects. Patients visit clinics every few weeks for brief evaluations, creating large gaps in understanding how therapies actually affect day-to-day cognitive function.
Digital biomarkers from continuous multimodal monitoring provide objective, high-resolution data on cognitive changes. This enables earlier go/no-go decisions, better responder identification, and more sensitive endpoints that can reduce trial sizes and durations.
For companies developing treatments across neurology, psychiatry, rare diseases, and aging-related conditions, General Cognitive's platform offers a standardized infrastructure for cognitive measurement that scales across therapeutic areas.
Continuous digital measurement replacing subjective clinical scales with objective behavioral data
Identify treatment responders early using fine-grained cognitive and behavioral signatures
Unified measurement framework enables comparisons across therapeutic areas and populations
Real-time monitoring of treatment effects on attention, memory, executive function, and mood
Endpoints designed for FDA and EMA acceptance with validation documentation
Our platform supports cognitive measurement across diverse conditions and populations
Multiple sclerosis, Parkinson's disease, epilepsy, stroke rehabilitation
Depression, anxiety, bipolar disorder, schizophrenia
Autism spectrum disorder, ADHD, developmental delays
Mild cognitive impairment, Alzheimer's disease, frontotemporal dementia
Diabetes-related cognitive decline, chronic kidney disease, liver disease
Genetic disorders with cognitive manifestations, pediatric metabolic conditions
Earlier detection of treatment effects with continuous monitoring vs. periodic assessments
More sensitive endpoints require fewer participants to detect meaningful differences
Identify responders and optimize patient selection for Phase 2/3 trials
Join leading therapeutics companies using our platform for next-generation cognitive endpoints
Schedule a Consultation